PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsInamrinone
Inamrinone
Amrinone (inamrinone) is a small molecule pharmaceutical. Inamrinone was first approved as Inocor on 1984-07-31. It is used to treat cardiogenic shock, dilated cardiomyopathy, heart failure, and low cardiac output in the USA. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A and cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Amrinone (discontinued: Amrinone, Inocor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Inamrinone lactate
Tradename
Company
Number
Date
Products
INOCORSanofiN-018700 DISCN1984-07-31
1 products
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01C: Cardiac stimulants excl. cardiac glycosides
C01CE: Phosphodiesterase inhibitors, cardiac stimulant
C01CE01: Amrinone
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameInamrinone
INNamrinone
Description
Amrinone is a 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. It has a role as an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
Classification
Small molecule
Drug classcardiotonics (amrinone type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1cc(-c2ccncc2)c[nH]c1=O
Identifiers
PDB
CAS-ID60719-84-8
RxCUI
ChEMBL IDCHEMBL12856
ChEBI ID
PubChem CID3698
DrugBankDB01427
UNII IDJUT23379TN (ChemIDplus, GSRS)
Target
Agency Approved
PDE3A
PDE3A
PDE3B
PDE3B
Organism
Homo sapiens
Gene name
PDE3A
Gene synonyms
NCBI Gene ID
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Protein synonyms
cAMP phosphodiesterase, myocardial cGMP-inhibited, cGI-PDE, CGI-PDE A, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited cAMP phosphodiesterase, Cyclic GMP-inhibited phosphodiesterase A, phosphodiesterase 3A, cGMP-inhibited
Uniprot ID
Mouse ortholog
Pde3a (54611)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (Q9Z0X4)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 793 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,043 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use